摘要
目的比较分析1,6-二磷酸果糖注射液联合肌苷、1,6-二磷酸果糖注射液及磷酸肌酸3种方案治疗小儿支气管肺炎合并心肌损害的成本-效果。方法将120例支气管肺炎合并心肌损害的患儿按随机数字表法分为果糖联合组、果糖组和磷酸肌酸组3组,每组40例。3组患儿均在接受相同基础治疗的基础上,果糖联合组给予1,6-二磷酸果糖(200 mg·kg-1·d-1)、肌苷注射液(0.2 g·d-1)静脉滴注;果糖组给予1,6-二磷酸果糖注射液(200 mg·kg-1·d-1)、磷酸肌酸组给予磷酸肌酸注射液(0.5 g·d-1)静脉滴注。3组均治疗7 d为1个疗程。观察3组患儿的治愈率,运用药物经济学原理对3种治疗方案进行成本-效果分析。结果果糖联合组、果糖组及磷酸肌酸组的治愈率分别为87.5%、75.0%及92.5%;主药治疗成本分别为187.6元、186.2元、518.7元;主药成本效果比分别为2.14、2.48、5.61。结论 1,6-二磷酸果糖联合肌苷为治疗小儿支气管肺炎合并心肌损害的经济有效的治疗方案。
Objective To compare the cost-effectiveness of fructose 1,6-bisphosphate, phospho-creatine and fructose 1,6-bisphosphate combined with inosine for pneumonia complicated by myocardial damage in children. Methods On the basis of basic treatment, 120 patients with bronchopneumonia were randomly treated with fructose 1,6-bisphosphate injection 200 mg·kg^-1·d^-1 （fructose group, n=40）, phosphocreatine injection 0.5 g·d^-1（phosphocreatine group, n=40） or fructose 1,6-bisphosphate injection 200 mg·kg^-1·d^-1 combined with inosine injection 0.5 g·d^-1 （combined fructose and inosine group, n=40） for 7 days. The cure rate was observed in the three groups. The cost-effectiveness was analyzed using the principles of pharmacoeconomics. Results The cure rate, main drug costs and main drug cost-effectiveness ratio were, respectively,87.5%,187.6 yuan RMB and 2.14 in combined fructose and inosine group, 75.0%,186.2 yuan RMB and 2.48 in fructose group, and 92.5%,518.7 yuan RMB and 5.61 in phosphocreatine group.Conclusion The combined treatment with fructose 1,6-bisphosphate and inosine is economical and effective for pneumonia complicated by myocardial damage in children.
出处
《实用临床医学（江西）》
CAS
2014年第7期68-70,共3页
Practical Clinical Medicine
基金
湛江市科技攻关计划项目(2012C3105075)
